Effects of sodium-glucose cotransporter 2 inhibitors on cause-specific cardiovascular death in patients with CKD
Clinical Trial registry name and registration number: ClinicalTrials.gov Identifiers: NCT02065791 (CREDENCE), NCT03036150 (DAPA-CKD), NCT03594110 (EMPA-KIDNEY).
Main Authors: | Fletcher, RA, Herrington, WG, Agarwal, R, Mayne, KJ, Arnott, C, Jardine, MJ, Mahaffey, KW, Perkovic, V, Staplin, N, Wheeler, DC, Chertow, GM, Heerspink, HJL, Neuen, BL |
---|---|
Format: | Journal article |
Language: | English |
Published: |
American Society of Nephrology
2024
|
Similar Items
-
Bioimpedance in CKD: an untapped resource?
by: Mayne, KJ, et al.
Published: (2022) -
In patients with type 2 diabetes and CKD, finerenone improved CV and kidney outcomes
by: Mayne, KJ, et al.
Published: (2022) -
Acute treatment effects on GFR in randomized clinical trials of kidney disease progression
by: Neuen, B, et al.
Published: (2021) -
Conventional and genetic evidence on the association between adiposity and CKD
by: Zhu, P, et al.
Published: (2020) -
In CKD, the kidney failure risk equation predicted 2-y risk for ESKD better than eGFR alone
by: Aguilar-Ramirez, D, et al.
Published: (2022)